Aqara To Unveil New Smart Home Devices at IFA 2023, Embracing the Future of Connected Living
31.8.2023 10:00:00 EEST | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its attendance at this year’s IFA show, where it will unveil multiple new smart home devices. These include the Smart Lock U200, the Camera E1, the Dual Relay Module T2, the Ceiling Light T1M, and an EU-style wall outlet. Aqara will be showcasing these new devices along with other smart home technology and solutions at its booth (H22, 214).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831580646/en/
Aqara unveils new smart home devices at IFA 2023 (Photo: Business Wire)
With a commitment to making smart home technology more accessible to households worldwide, Aqara continues to expand its product portfolio to enable various home automation use cases. The five new products previewed at IFA are expected to become available for order in the coming months.
Smart Lock U200 - As a retrofit solution, Aqara’s new Smart Lock U200 offers the convenience of keyless home access to a broad user base. The lock operates with existing cylinders and requires no drilling or door modifications. As Aqara’s first Matter-over-Thread smart lock, the U200 will be interoperable with a wide array of smart home ecosystems and products. Using an Aqara NFC card or specified NFC-enabled mobile devices, users can unlock easier than ever before. Other secure access options include auto-unlock, fingerprints, PIN codes and mobile apps. Aqara also plans to initiate its first crowdfunding campaign on Kickstarter for the Smart Lock U200 later this year.
Camera E1 - Aqara is expanding its home surveillance camera portfolio with the 2K, Pan/Tilt Camera E1. Similar to other indoor home cameras from the Company, this new camera supports major third-party platforms like Apple Home (including HomeKit Secure Video), Amazon Alexa, and Google Home. Built upon Wi-Fi 6 and Bluetooth 5.2, the camera enables smoother live view and easier pairing experience. Other features of the E1 camera include AI-enabled person detection, person tracking and flexible storage options such as cloud storage, microSD card, and NAS storage.
Dual Relay Module T2 - The Dual Relay Module T2 is a versatile solution for home automation, allowing easy control of various devices ranging from lights, motorized window coverings, garage doors, boilers, to electric heaters and underfloor heating. Built upon Zigbee 3.0, the dual relay module features Matter-over-bridge support and is compatible with major third-party platforms. It also allows users to monitor energy consumption and ensures peace of mind with safety features like overheat protection, overload protection, and configurable power limits. Powered by AC (100-250V) or DC (24-60V), the 2-channel relay supports a total (and per-channel) loads of up to 10 Amps.
Ceiling Light T1M - Following the LED Strip T1, which was announced in August 2023, Aqara is introducing its second smart lighting device to the global market. With an approximate diameter of 50 centimeters, the Ceiling Light T1M offers a broad spectrum of hues from dimmable whites to 16 million vibrant colors, allowing users to set the atmospheric lighting for different occasions and moods. Additional features include an independently addressable RGB ring for gradient effects and integration into home automation, such as using the RGB ring as a status light to indicate potential threats like an open door or water leak. Similar to other Zigbee devices from Aqara, the Ceiling Light T1M features the low idle consumption, Matter-over-bridge support, and the wide compatibility with major platforms.
EU-style wall outlet - Finally, Aqara is introducing a smart wall socket for the EU market. This outlet allows easy control of plugged devices via mobile apps, voice assistants and home automation. It also helps users track energy consumption. Moreover, this new outlet can be configured to sense and report the status of the plugged device, making it possible to use the on/off status of an appliance as an automation trigger. For example, to close the curtains and dim the lights when the TV is turned on, or to notify the user when the washing machine finished the laundry. As a repeater of the Zigbee network, this socket outlet also enhances network reliability and responsiveness of other compatible smart home devices.
“Aqara is at the forefront of innovating the smart home experience, and these new products are a testament to our dedication. Each of them is crafted with the user's convenience and lifestyle in mind, reflecting our commitment to quality and innovation,” said Cathy You, Aqara Senior Vice President, Global Business and Strategy. “We invite everyone to join us at our booth to experience firsthand the future we're building together.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831580646/en/
Contact information
For Media Inquiries:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
